Adverum Biotechnologies, Inc. (NASDAQ: ADVM) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Mizuho from $40.00 to $22.00. They now have a "buy" rating on the stock.
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting [Yahoo! Finance]
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year? [Yahoo! Finance]